Value
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 7.0 |
| P/S | 5.9 |
| EV/EBITDA | 5.8 |
| Fwd P/E | 9.3 |
| PEG | 7.6 |
| Analyst target | 3.0 |
- ▸Forward P/E: 9.9x
- ▸PEG: 0.89
CPRX · Why this verdict
Why Catalyst Pharmaceuticals (CPRX) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business maintains a wide economic moat, 37% operating margins ranking best-in-class among peers, and a Piotroski F-Score of 8 out of 9—indicators of a durable competitive position generating returns well above the cost of capital across business cycles. Quality breakdown | Operating margins remain at or above 35% over the next 12 months, confirming that the moat is protecting the franchise from competitive erosion. | →Stable |
| CounterFree cash flow converts at 78% of reported net income—a quality flag—suggesting a gap between accounting earnings and actual cash generation; if this gap widens, reported margins may overstate the true cash economics of the business. | ||
Four consecutive quarters of earnings beats with an average EPS surprise of 27.5% reflects a pattern of consistently delivering results well above sell-side expectations—a track record that typically underpins sustained price appreciation over time. Catalyst track record | The beat streak extends beyond 6 consecutive quarters, with average EPS surprise remaining above 15%, sustaining the pattern of consistent outperformance. | →Stable |
| CounterAnalyst estimates have fallen 17.2% over the past 30 days, suggesting the sell side is resetting its models downward; if estimates are marked down sufficiently, future beats become mechanically easier without reflecting genuine business improvement, and the beat streak may not translate to price appreciation if it comes against a materially lower bar. | ||
At 31.37, the share price trades approximately 2% above the analyst consensus target of 30.76, producing a negative reward-to-risk profile; the asymmetry is deeply unfavorable, with a downside risk of roughly 15% and no meaningful upside to the analyst consensus at current levels. Price targets | Analyst consensus target rises above 36.00, creating more than 14% upside from the current price of 31.37 and converting the reward/risk to favorable for a new entry. | →Stable |
| CounterA four-for-four beat streak with wide moat characteristics may prompt upward analyst target revisions; if earnings continue outperforming by 20%-plus and targets are revised higher, the current premium to consensus could quickly look modest in retrospect. | ||
Two high-severity supplier concentration risks create tail risk for a business that has otherwise demonstrated exceptional earnings consistency; if either supply relationship is disrupted, the earnings trajectory that underpins the premium valuation could reverse sharply. Bear case | The beat streak extends beyond 8 consecutive quarters without a supply-disruption miss, demonstrating that the supplier relationships are operationally stable and the tail risk has not materialized at current business scale. | →Stable |
| CounterThe elevated put/call ratio of 16.69 may already be pricing in this tail risk; if no disruption materializes over the next several quarters, the bearish options overhang could unwind sharply and provide an additional price catalyst beyond the earnings beat dynamics. | ||
The business maintains a wide economic moat, 37% operating margins ranking best-in-class among peers, and a Piotroski F-Score of 8 out of 9—indicators of a durable competitive position generating returns well above the cost of capital across business cycles.
→StableQuality breakdown
- Expectation
- Operating margins remain at or above 35% over the next 12 months, confirming that the moat is protecting the franchise from competitive erosion.
CounterFree cash flow converts at 78% of reported net income—a quality flag—suggesting a gap between accounting earnings and actual cash generation; if this gap widens, reported margins may overstate the true cash economics of the business.
Four consecutive quarters of earnings beats with an average EPS surprise of 27.5% reflects a pattern of consistently delivering results well above sell-side expectations—a track record that typically underpins sustained price appreciation over time.
→StableCatalyst track record
- Expectation
- The beat streak extends beyond 6 consecutive quarters, with average EPS surprise remaining above 15%, sustaining the pattern of consistent outperformance.
CounterAnalyst estimates have fallen 17.2% over the past 30 days, suggesting the sell side is resetting its models downward; if estimates are marked down sufficiently, future beats become mechanically easier without reflecting genuine business improvement, and the beat streak may not translate to price appreciation if it comes against a materially lower bar.
At 31.37, the share price trades approximately 2% above the analyst consensus target of 30.76, producing a negative reward-to-risk profile; the asymmetry is deeply unfavorable, with a downside risk of roughly 15% and no meaningful upside to the analyst consensus at current levels.
→StablePrice targets
- Expectation
- Analyst consensus target rises above 36.00, creating more than 14% upside from the current price of 31.37 and converting the reward/risk to favorable for a new entry.
CounterA four-for-four beat streak with wide moat characteristics may prompt upward analyst target revisions; if earnings continue outperforming by 20%-plus and targets are revised higher, the current premium to consensus could quickly look modest in retrospect.
Two high-severity supplier concentration risks create tail risk for a business that has otherwise demonstrated exceptional earnings consistency; if either supply relationship is disrupted, the earnings trajectory that underpins the premium valuation could reverse sharply.
→StableBear case
- Expectation
- The beat streak extends beyond 8 consecutive quarters without a supply-disruption miss, demonstrating that the supplier relationships are operationally stable and the tail risk has not materialized at current business scale.
CounterThe elevated put/call ratio of 16.69 may already be pricing in this tail risk; if no disruption materializes over the next several quarters, the bearish options overhang could unwind sharply and provide an additional price catalyst beyond the earnings beat dynamics.
TrendMatrix Research · core thesis
Engine thesis — one sentence
A high-quality pharmaceutical business with a wide economic moat, 37% margins, and four consecutive earnings beats averaging 27.5% upside surprise is a compelling long-term franchise, but the share price now trades above the analyst consensus target, estimates have fallen 17.2% over 30 days, and the risk/reward is deeply unfavorable—this is a hold for existing positions, not an entry.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
8.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 8.2 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 5.9 |
| FCF quality | 5.8 |
| Moat | 8.4 |
| Rule of 40 | 5.5 |
| Piotroski F | 8.9 |
- ▸Strong margins: 37%
- ▸Earnings quality warning: 78% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
4.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.9 |
| EPS growth | 4.2 |
Momentum
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 2.7 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 8.1 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 5.1 |
| erm sentiment | 0.0 |
- ▸Estimates falling as sentiment proxy (-33.3%)
Insider
5.0/10data confidence 50%Peer rank
7.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.2 |
| quality rank | 8.8 |
| growth rank | 4.3 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.3 |
| support resistance | 1.5 |
| 52w position | 9.3 |
Risk (lower is worse)
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.6 |
| days to cover | 6.7 |
| volatility | 10.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 8.5 |
| debt equity | 10.0 |
- ▸High IV: 101%
- ▸Above max pain $25
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 1.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Estimates down -33.3% (30d)
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (7)
- MOMENTUM:5.2>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:29d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.0=NEGATIVE
Warning (1)
- MOMENTUM:5.2<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
-0.96
Upside
-14.5%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 29d with 4/4 beat streak
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:5.2>=4.5. Top dim: Quality at 8.3; weakest: Sentiment at 3.7. No conviction either direction.
The strongest dimensions are Quality at 8.3, Peer rank at 7.1, and Risk (lower is worse) at 6.8; the weakest are Sentiment at 3.7, Growth at 4.0, and Technical at 4.4. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.96 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Best In Class Margins
Trip ifOperating margin compresses below 30% for 2 consecutive quarters from the current 37% level.
- P2Perfect Earnings Beat Streak
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, breaking the 4-quarter beat streak.
- P3Price Above Analyst Target
Trip ifAnalyst consensus target rises above 36.00, creating more than 14% upside from current price of 31.37.
- P4Dual Supplier Concentration Risk
Trip ifEPS beat streak extends beyond 8 consecutive quarters with average surprise remaining above 15%, confirming supplier relationships have not disrupted earnings delivery.